Logo (500 x 500 px) transparent background.png
PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease
September 16, 2024 04:00 ET | C4X Discovery Holdings PLC
C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024 08:05 ET | Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Biora-tm_rgb.jpg
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET | Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora-tm_rgb.jpg
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET | Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
May 21, 2024 08:00 ET | Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Biora-tm_rgb.jpg
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET | Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
ABIVAX_Logo-RGB.png
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024 02:30 ET | Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Mean Plasma Tofacitinib Concentration
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024 08:00 ET | Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
ABIVAX_Logo-RGB.png
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET | Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Stacked logo.png
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
March 20, 2024 20:05 ET | Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...